Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma trial registry — 500 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Anaxis Pharma clinical trials

Registry index of 500 ClinicalTrials.gov studies linked to Anaxis Pharma programs — each row shows trial ID, program name, phase, status, and indication.

Anaxis Pharma trial registry — 500 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Anaxis Pharma.

  1. R2810-ONC-2045 — Phase 2

    Clinical update

  2. NS229-P2-01 — Phase 2

    Clinical update

  3. DCC-3116-01-001 — Phase 2

    Clinical update

  4. BLCL-TOF-EU-01 — Phase 1

    Clinical update

  5. BLCL-RUX-PIL01 — Phase 1

    Clinical update

  6. BLCL-LIS-PIL01 — Phase 1

    Clinical update

  7. AP-recAP-CSA-RD-0201 — Phase 2

    Clinical update

  8. AN OPEN-LABEL for Intramuscular administration of… — Phase 1

    Clinical update

Trial registry

500 studies
  63. 2023-507344-36-01

    CMP-001-009

    Phase 2 active small_molecule

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    CTIS ↗
  76. 2023-507777-18-00

    Lacutamab

    Phase 2 active small_molecule

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    CTIS ↗
  105. 2023-508845-41-00

    bimekizumab

    Phase 3 active small_molecule

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    CTIS ↗
  109. 2023-509067-24-00

    AL8326

    Phase 2 active small_molecule

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    CTIS ↗
  110. 2023-509067-24-01

    AL8326

    Phase 2 active small_molecule

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    CTIS ↗
  118. 2023-509143-27-00

    ASND0029

    Phase 2 active small_molecule

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    CTIS ↗
  139. 2023-509399-40-00

    AN OPEN-LABEL for Intramuscular administration of…

    Phase 1 active other

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    CTIS ↗
  164. 2024-510714-32-00

    ET-20-049

    Phase 2 active small_molecule

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    CTIS ↗
  179. 2024-511188-26-00

    KT-US-679-0788

    Phase 3 active small_molecule

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    CTIS ↗
  188. 2024-511526-31-00

    01API2024

    Phase 1 active other

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    CTIS ↗
  228. 2024-512715-42-00

    INZ-701

    Phase 2 active small_molecule

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    CTIS ↗
  244. 2024-513023-17-00

    MaaT013

    Phase 3 active small_molecule

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    CTIS ↗
  301. 2024-515180-56-00

    OP0595-6

    Phase 3 active small_molecule

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    CTIS ↗
  332. 2024-516216-16-00

    FMGX-CS-302

    Phase 3 active small_molecule

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    CTIS ↗
  388. 2024-518450-16-00

    CT-P1-002

    Phase 2 active other

    Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure

    CTIS ↗
  398. 2024-519233-33-00

    FLECA-ED

    Phase 3 active small_molecule

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    CTIS ↗
  409. 2024-519660-40-00

    02API2024

    Phase 1 active other

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    CTIS ↗
  450. 2025-521936-12-00

    OBEZ-303

    Phase 3 active small_molecule

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    CTIS ↗
  459. 2025-522345-21-00

    A148_01PK2408

    Phase 1 active other

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    CTIS ↗
  467. 2025-522752-45-00

    DUO2025_01

    Phase 3 active small_molecule

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    CTIS ↗
  470. 2025-522857-20-00

    Cizutamig

    Phase 2 active small_molecule

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    CTIS ↗
  471. 2025-522921-37-00

    An open-label for inteneded for treatment of - ac…

    Phase 1 active other

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    CTIS ↗
  477. 2025-523115-11-00

    A160_01AD2502

    Phase 1 active other

    Phase I study in healthy participants. Intended indication: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.